Valuation : Neuland Laboratories Limited

Market Cap 291B 3.07B 2.64B 2.48B 2.27B 4.24B 4.27B 29.35B 11.43B 148B 11.54B 11.29B 478B P/E 2027 *
61.5x
P/E 2028 * 47.1x
Enterprise Value 293B 3.1B 2.67B 2.5B 2.29B 4.27B 4.31B 29.61B 11.53B 150B 11.64B 11.39B 482B EV / Sales 2027 *
12x
EV / Sales 2028 * 9.96x
Free-Float
62.26%
Yield 2027 *
0.1%
Yield 2028 * 0.13%
1 day-1.21%
1 week-2.51%
Current month-1.27%
1 month+17.39%
3 months+34.25%
6 months+77.23%
Current year+49.06%
1 week 22,400
Extreme 22400
23,325
1 month 19,252.75
Extreme 19252.75
23,899
Current year 11,500
Extreme 11500
23,899
1 year 11,500
Extreme 11500
23,899
3 years 3,424.45
Extreme 3424.45
23,899
5 years 965.85
Extreme 965.85
23,899
10 years 247.3
Extreme 247.3
23,899
Manager TitleAgeSince
Chief Executive Officer 47 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member 50 01/01/2002
Chairman 82 07/01/1984
Director/Board Member 47 01/03/2007
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%-2.51%+55.03%+524.77% 3.11B
-0.04%-1.40%+57.16%+108.15% 1,034B
+1.17%+4.76%+56.42%+73.50% 671B
-0.58%+0.80%+22.82%+75.58% 460B
-0.81%-1.23%+28.51%+37.51% 353B
-1.20%+4.91%+24.92%+45.82% 309B
-0.61%+0.99%-0.82%+13.08% 255B
+0.29%+1.63%+56.46%+73.00% 240B
-0.79%+1.62%-16.70%-54.18% 207B
+1.08%+1.59%+33.83%+97.29% 188B
Average -0.59%+0.90%+31.76%+99.45% 371.99B
Weighted average by Cap. -0.57%+1.04%+38.07%+67.95%

Financials

2027 *2028 *
Net sales 24.43B 258M 222M 209M 191M 356M 359M 2.47B 961M 12.49B 971M 950M 40.22B 29.27B 310M 266M 250M 229M 427M 430M 2.96B 1.15B 14.96B 1.16B 1.14B 48.17B
Net income 4.8B 50.76M 43.67M 40.98M 37.5M 69.99M 70.54M 485M 189M 2.45B 191M 186M 7.9B 6.26B 66.27M 57.02M 53.51M 48.96M 91.37M 92.1M 633M 247M 3.2B 249M 243M 10.31B
Net Debt 2.56B 27.09M 23.31M 21.88M 20.01M 37.36M 37.65M 259M 101M 1.31B 102M 99.52M 4.22B 979M 10.36M 8.91M 8.37M 7.65M 14.28M 14.4M 98.96M 38.54M 500M 38.9M 38.06M 1.61B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
04/09/26 22,643.30 -1.21% 1,382
03/09/26 ₹22,920.60 -0.15% 677
02/09/26 ₹22,955.85 -0.35% 2,101
01/09/26 ₹23,036.00 +0.44% 1,283
31/08/26 ₹22,934.20 -1.25% 2,327
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
22,920.60INR
Average target price
24,334.75INR
Spread / Average Target
+6.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock